• 1. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 4. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Sugar alcohols
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbohydrates and carbohydrate conjugates Sugar alcohols

Professional Introduction to 2,3-Dihydro Acrivastine (CAS No. 87849-01-2)

2,3-Dihydro Acrivastine (CAS No. 87849-01-2) is a significant compound in the field of pharmaceutical chemistry, renowned for its pharmacological properties and therapeutic applications. This introduction delves into the compound's chemical structure, mechanism of action, recent research findings, and its potential in modern medicine.

The chemical name of this compound underscores its structural relationship to Acrivastine, a well-known antihistamine. The transformation from Acrivastine to 2,3-Dihydro Acrivastine involves the addition of hydrogens at the 2 and 3 positions of the acrivastine molecule. This modification enhances the compound's stability and bioavailability, making it a promising candidate for further pharmaceutical development.

In terms of molecular structure, 2,3-Dihydro Acrivastine exhibits a tricyclic aromatic system with substituents that contribute to its pharmacological activity. The presence of hydroxyl and amino groups in its structure allows for interactions with various biological targets, primarily histamine H1 receptors. This interaction is pivotal in its function as an antihistamine, providing relief from allergic symptoms such as itching, sneezing, and runny nose.

Recent studies have highlighted the compound's potential in treating allergic rhinitis and urticaria. The enhanced stability of 2,3-Dihydro Acrivastine compared to its parent compound makes it more suitable for oral administration and prolonged therapeutic effects. Research has demonstrated that this derivative maintains the efficacy of Acrivastine while reducing the incidence of side effects such as drowsiness and dry mouth.

The mechanism of action of 2,3-Dihydro Acrivastine involves competitive binding to histamine H1 receptors on peripheral nerve endings and blood vessels. By blocking these receptors, the compound effectively prevents histamine from exerting its inflammatory effects. This mechanism is particularly relevant in conditions where histamine release is a key pathophysiological process.

One of the most compelling aspects of 2,3-Dihydro Acrivastine is its potential in combination therapies. Current research suggests that when paired with other anti-allergic agents, such as corticosteroids or leukotriene inhibitors, it can provide synergistic benefits. This combination approach could lead to more comprehensive management strategies for patients suffering from severe allergic conditions.

The pharmacokinetic profile of 2,3-Dihydro Acrivastine has been extensively studied to optimize dosing regimens and minimize adverse effects. Studies indicate that the compound has a moderate half-life, allowing for once or twice daily dosing without significant accumulation. This characteristic makes it highly convenient for patients requiring long-term treatment.

In conclusion, 2,3-Dihydro Acrivastine (CAS No. 87849-01-2) represents a significant advancement in the treatment of allergic disorders. Its improved stability and reduced side effects make it a valuable addition to the pharmacopeia. Ongoing research continues to explore its potential in various therapeutic contexts, promising further refinements in allergy management.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)